1. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. (1st January 2018) Authors: Tang, Xiaolong; Chen, Longzhou; Li, Amin; Cai, Shiyu; Zhang, Yinci; Liu, Xueke; Jiang, Zhenyou; Liu, Xinkuang; Liang, Yong; Ma, Dong Journal: Drug delivery Issue: Volume 25:Number 1(2018) Page Start: 1484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. RETRACTED ARTICLE: Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study. (17th November 2018) Authors: Rong, Ling; Zhou, Shuping; Liu, Xinkuang; Li, Amin; Jing, Tao; Liu, Xueke; Zhang, Yinci; Cai, Shiyu; Tang, Xiaolong Journal: Artificial cells, nanomedicine, and biotechnology Issue: Volume 46:Number 8(2018) Page Start: 1708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study. (17th November 2018) Authors: Rong, Ling; Zhou, Shuping; Liu, Xinkuang; Li, Amin; Jing, Tao; Liu, Xueke; Zhang, Yinci; Cai, Shiyu; Tang, Xiaolong Journal: Artificial cells, nanomedicine, and biotechnology Issue: Volume 46:Number 8(2018) Page Start: 1708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗